and weight.

DRUG2 trials

Sponsors

Zenas Biopharma (USA) LLC

Conditions

Non-active Secondary Progressive Multiple Sclerosis (SPMS)Primary Progressive Multiple Sclerosis (PPMS)

Phase 3

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis

Not yet recruitingCTIS2025-524316-11-00

Zenas Biopharma (USA) LLCPrimary Progressive Multiple Sclerosis (PPMS)

Target: 126Updated: 2026-05-19

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Not yet recruitingCTIS2025-524322-18-00

Zenas Biopharma (USA) LLCNon-active Secondary Progressive Multiple Sclerosis (SPMS)

Target: 177Updated: 2026-06-23